In Vitro Analysis of Cancer Prevention by a Mycobacterial Antigen Complex and of Cancer-promoted Inhibition of Immune Reactions

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 1996 Jan 1

PMID 8954170

Authors

H Maes

C Cocito

Affiliations

Soon will be listed here.

Abstract

The antigen complex A60 of Mycobacterium bovis bacillus Calmette-Guérin protected mice against experimental tuberculous infection, and prevented cancer development after challenge with EMT 6 cells. Although humoral and cellular immune reactions elicited by A60 in vivo remained unaffected in cases of tumor rejection, they were suppressed in the case of neoplastic growth. In the present work, these in vivo observations were analyzed by in vitro techniques. Activated macrophages played a major role, and cytolytic T lymphocytes a minor role, in A60-promoted cancer cell cytolysis leading to tumor rejection. In vitro, EMT 6 cells weakly inhibited the proliferation of A60-specific B lymphocytes and strongly inhibited the functions of activated macrophages. However, the collapse of both humoral and cellular immune reactions during the course of cancer development was also accompanied by an inhibitory action of EMT 6 cells on the multiplication and functions of A60-specific T lymphocytes. Tumor-dependent repression of macrophage activation was therefore due to both a direct action of tumor cells on macrophages and an indirect one via inhibition of macrophage-activating T cell functions. On the other hand, tumor-induced collapse of the anti-A60 Ig synthesis was mainly due to inhibition of B-cell-activating T cells, with a weaker direct effect of tumor cells on B lymphocytes. Consequently, A60 and tumor cells exert opposite effects on the immune system at several levels.

References

Gilot P, Coene M . Thermostable macromolecular antigens from mycobacteria. Can J Microbiol. 1994; 40(8):605-11. DOI: 10.1139/m94-097. View

Spiess P, Yang J, Rosenberg S . In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst. 1987; 79(5):1067-75. View

Milas L, Scott M . Antitumor activity of Corynebacterium parvum. Adv Cancer Res. 1978; 26:257-306. DOI: 10.1016/s0065-230x(08)60090-1. View

Beschin A, Brijs L, De Baetselier P, Cocito C . Mycobacterial proliferation in macrophages is prevented by incubation with lymphocytes activated in vitro with a mycobacterial antigen complex. Eur J Immunol. 1991; 21(3):793-7. DOI: 10.1002/eji.1830210336. View

Benoit C, Beschin A, Desmecht M, DEKEYSER P, Cocito C . Delayed hypersensitivity reactions by the mycobacterial antigen A60 and cutaneous testing in tuberculosis. Med Microbiol Immunol. 1989; 178(2):105-12. DOI: 10.1007/BF00203306. View

Askenase P . Delayed-type hypersensitivity recruitment of T cell subsets via antigen-specific non-IgE factors or IgE antibodies: relevance to asthma, autoimmunity and immune responses to tumors and parasites. Chem Immunol. 1992; 54:166-211. View

Belldegrun A, Muul L, Rosenberg S . Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res. 1988; 48(1):206-14. View

Urban J, Schreiber H . Tumor antigens. Annu Rev Immunol. 1992; 10:617-44. DOI: 10.1146/annurev.iy.10.040192.003153. View

Hubbard R, FLORY C, Collins F, Cocito C . Immunization of mice with the antigen A60 of Mycobacterium bovis BCG. Clin Exp Immunol. 1992; 88(1):129-31. PMC: 1554356. DOI: 10.1111/j.1365-2249.1992.tb03051.x. View

10.

Rubbert A, Manger B, Lang N, Kalden J, PLATZER E . Functional characterization of tumor-infiltrating lymphocytes, lymph-node lymphocytes and peripheral-blood lymphocytes from patients with breast cancer. Int J Cancer. 1991; 49(1):25-31. DOI: 10.1002/ijc.2910490106. View

11.

Bartholomew B . A rapid method for the assay of nitrate in urine using the nitrate reductase enzyme of Escherichia coli. Food Chem Toxicol. 1984; 22(7):541-3. DOI: 10.1016/0278-6915(84)90224-2. View

12.

Vaage J, Pepin K . Morphological observations during developing concomitant immunity against a C3H/He mammary tumor. Cancer Res. 1985; 45(2):659-66. View

13.

Young M, Wright M, Coogan M, Young M, Bagash J . Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor beta. Cancer Immunol Immunother. 1992; 35(1):14-8. PMC: 11038123. DOI: 10.1007/BF01741049. View

14.

Kawase I, Komuta K, Namba M, Yokota S, Ogura T, Kishimoto S . Macrophage tumoricidal activity as a possible antitumor mechanism associated with the local injection of allogeneic spleen cells into rats. Cancer Res. 1986; 46(3):1047-54. View

15.

Ding A, Nathan C, Stuehr D . Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol. 1988; 141(7):2407-12. View

16.

Rockwell S, Kallman R, Fajardo L . Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J Natl Cancer Inst. 1972; 49(3):735-49. View

17.

Brooks W, NETSKY M, Normansell D, Horwitz D . Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J Exp Med. 1972; 136(6):1631-47. PMC: 2139329. DOI: 10.1084/jem.136.6.1631. View

18.

Cocito C, Baelden M, Benoit C . Immunological properties of antigen 60 of BCG. Induction of humoral and cellular immune reactions. Scand J Immunol. 1987; 25(6):579-85. DOI: 10.1111/j.1365-3083.1987.tb01084.x. View

19.

Kersey J, Spector B, GOOD R . Immunodeficiency and cancer. Adv Cancer Res. 1973; 18:211-30. DOI: 10.1016/s0065-230x(08)60753-8. View

20.

Young M, Wheeler E, Newby M . Macrophage-mediated suppression of natural killer cell activity in mice bearing Lewis lung carcinoma. J Natl Cancer Inst. 1986; 76(4):745-50. DOI: 10.1093/jnci/76.4.745. View